Early PrEgnancy Complications Testing (ExPECT)

Non-invasive Prenatal Testing for the Presymptomatic Detection of Pregnancy Complications

The aim of this study is the early (presymptomatic) detection of pregnancy complications, which could contribute to a preventive treatment.

Study Overview

• Status: Recruiting
• Conditions: Pregnancy Complications
• Intervention / Treatment: Diagnostic test: Blood samples

Detailed Description

Prenatal screening for an early detection of fetal abnormalities and pregnancy related complications is of great importance for both the fetus and the mother. The current follow-up consists of a physical screening (maternal blood pressure, edemas, weight, fundus altitude...), lab screenings (urine culture for screening asymptomatic bladder infection, urine stick for preeclampsia, sugar test for gestational diabetes, measuring cervix length for premature birth, Group B streptococcus screening), ultrasound monitoring (structural inspection, biometrics, placental function ...) and fetal monitoring with cardiotocography.

The recent introduction of the Non-Invasive Prenatal Testing (NIPT) caused a major change in prenatal diagnosis. NIPT allows the early (12 weeks gestational age) detection of chromosomal abnormalities, such as trisomy 21, with a very high sensitivity and specificity.

Trisomy 21 is with its incidence of 1/1000 live births only the tip of the iceberg of many other fetal abnormalities and gestational complications that can occur. Pregnancy complications, such as pre-eclampsia, intra-uterine growth retardation (IUGR) and preterm birth have a much higher incidence (up to 5-8% of all pregnancies) and are an important cause of maternal and neonatal morbidity and mortality.

The aim of this study is the early (presymptomatic) detection of pregnancy complications, which could contribute to a preventive treatment. Studies have shown that the major cause of these complications originate from defects in spiral artery remodeling and trophoblast invasion or an abnormal functioning placenta, during the 1st or 2nd trimester. Insufficient oxygen and nutrient flow to the placenta, caused by abnormal (narrowed diameter) spiral arteria, is the most proven underlying origin. These obstructing conditions can lead to a placenta in stress (hypoxia), and therefore potentially a fetus in stress (IUGR). General known is that these pathologies will lead to a different gene expression, which can be investigated by direct analysis of placental RNA (transcriptome) and DNA (methylation profiling). During the last decade, several high impact researchers (for example the research groups of Dennis Lo and Stephen Quake, founders of the current worldwide NIPT screening) have investigated gene expression profiles in the placenta in normal and complicated pregnancies, by analyzing the placental cell free DNA and RNA present in maternal plasma. Very recent findings indicate a huge potential in non-invasively profiling the placental transcriptome and methylome. Advances in next-generation sequencing and molecular analysis made it possible to measure circulating nucleic acids to improve the investigator's understanding of placental pathology and develop novel non-invasive biomarkers for pregnancy complications and monitoring high-risk pregnancies.

• Study Type: Interventional
• Enrollment (Estimated): 250
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Isabelle Dehaene, MD; Phone Number: 003293327817; Email: isabelle.dehaene@uzgent.be
• Study Contact Backup: Name: Eline Meireson, MSc; Email: eline.meireson@uzgent.be

Study Locations

• Belgium
  • Ghent, Belgium, 9000
    • Recruiting
    • Ghent University Hospital - Women's Clinic
    • Contact: Sara Somers; Email: Sara.Somers@uzgent.be

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Every pregnant woman, speaking and understanding Dutch, French or English

Exclusion Criteria:

• not able to understand and adhere to the informed consent and study procedures

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Diagnostic
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Other: Pregnancy complication; Intervention: blood samples	Diagnostic test: Blood samples; Bood samples during prenatal and postnatal visits

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Optimizing and validating a non-invasive prenatal genetic screening for the early presymptomatic detection of pregnancy complications	The placental transcriptome represents gene expression in this specific tissue. Abnormalities in the placenta have been shown to lead to aberrant gene expression patterns. The RNA biomarker (transcript) analysis will be performed by RNA sequencing of cell free RNA by next generation sequencing. After sequencing, RNA molecules will be identified and transcripts will be quantified and evaluated between normal and pregnancies with complications. This will provide information regarding aberrant expressed genes and transcripts. Statistical analysis between both groups will be performed to identify and subsequently validate biomarkers that can be used to presymptomatically prediction pregnancy complications.	Through study completion, an average of 30 weeks
Optimizing and validating a non-invasive prenatal genetic screening for the early presymptomatic detection of pregnancy complications	Epigenetic modifications (eg. DNA methylation) can alter gene expression, without altering the DNA sequence itself. DNA methylation can be investigated by bisulfite conversion of the DNA followed by next-generation sequencing. It has been shown that complicated pregnancies have aberrant methylation profiles of placental DNA. By analyzing the methylation profile of the cell free DNA of normal and complicated pregnancies and performing a statistical analysis, we will identify biomarkers and set-up a prediction model for the prediction of pregnancy complication.	Through study completion, an average of 30 weeks

Collaborators and Investigators

• Sponsor: University Hospital, Ghent
• Investigators: Principal Investigator: Isabelle Dehaene, MD, UZ Gent

Study record dates

Study Major Dates

• Study Start (Actual): April 1, 2019
• Primary Completion (Estimated): December 31, 2024
• Study Completion (Estimated): December 31, 2024

Study Registration Dates

• First Submitted: April 1, 2019
• First Submitted That Met QC Criteria: September 4, 2019
• First Posted (Actual): September 6, 2019

Study Record Updates

• Last Update Posted (Estimated): January 1, 2024
• Last Update Submitted That Met QC Criteria: December 27, 2023
• Last Verified: December 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Female Urogenital Diseases and Pregnancy Complications; Urogenital Diseases; Pregnancy Complications
• Other Study ID Numbers: EC/2019/0056

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No